Novo Nordisk A/S and Eli Lilly and Co welcome heavy bullish news! It is rumored that weight loss drugs may enter the U.S. medical insurance system.
According to reports, the government led by usa President Biden is proposing a regulation that would require payment for weight loss drugs, potentially expanding access to these medications for millions of obese americans and creating a massive new medical bill for elected President Donald Trump.
Novo Nordisk Says White House Obesity Plan Is Step in Right Direction -- Interview
European Equities Traded in the US as American Depositary Decline in Tuesday Trading
Benzinga Market Summary: Best Buy And Kohl's Cut Outlook, Biden Admin Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs, PResident-Elect Trump Threatens Tariffs On China, Canada And Mexico
Express News | US weight loss drug concept stocks rose across the board, with Viking Therapeutics up more than 5%, Altimmune and Eli Lilly and Co up more than 3%, Sorrento Biologicals and Novo-Nordisk A/S up more than 2%. Previously, US President Biden proposed medical
At the beginning of trading, US stocks related to weight loss drugs rose broadly.
Gelonghui on November 26th: eli lilly and co rose by 3.15%, Shuodi Biology rose by 2.65%, novo-nordisk a/s rose by 2.27%. Earlier, USA President Biden proposed medical insurance and medical subsidy coverage for weight loss drugs.